Sargent Bickham Lagudis’s Verastem VSTM Stock Holding History

Sargent Bickham Lagudis’s Portfolio VSTM Stock Details VSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-121	Closed	-$3K	–	1023
2021 Q4	$3K	Buy	+121	New	+$3.82K	﹤0.01%	869

Other funds holding VSTM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Sargent Bickham Lagudis's VSTM Position: Q1 2022 in Review

Sargent Bickham Lagudis sold out of Verastem (VSTM) in Q1 2022, closing a stake of 121 shares — an estimated $3K sold.

Sargent Bickham Lagudis first reported a position in VSTM in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 141 funds tracked by Wall St. Rank hold VSTM as of Q1 2022.

Sargent Bickham Lagudis reported no remaining Verastem position as of Q1 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 121 Verastem shares in Q1 2022, an estimated $3K.
Sargent Bickham Lagudis first reported a position in Verastem in Q4 2021 and held it in 1 quarter.
Sargent Bickham Lagudis's Verastem position peaked at $3K in Q4 2021.
141 funds tracked by Wall St. Rank held Verastem as of Q1 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2022, filed 27 Apr 2022.